MRI Study Reveals Hypothalamic Atrophy Across Multiple Subregions in Narcolepsy Type 1

Adults with narcolepsy type 1 (NT1) exhibit measurable reductions in hypothalamic volume across most subregions of the structure, according to new findings from the largest MRI investigation of its kind published in SLEEP.¹ The results add structural neuroimaging evidence to a disease whose neuropathology has largely been studied through postmortem samples collected decades after onset.

NT1 is a chronic neurological disorder marked by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, sleep paralysis, and disrupted nocturnal sleep. It is driven by the selective loss of orexin-producing neurons in the posterior hypothalamus, a small population of roughly 70,000 cells with widespread projections throughout the brain. Though an autoimmune mechanism is widely accepted, the precise pathological cascade remains uncertain, in part because postmortem studies examine brains long after the acute phase of neuronal loss. The real-world burden of these symptoms remains substantial: Data presented at the Sleep 2026 Annual Meeting from a cross-sectional survey of 247 adults with NT1 found that 91.2% reported disturbed nighttime sleep, 77.0% had cognitive challenges, and 84.5% reported cataplexy, with severe excessive daytime sleepiness persisting in most patients despite 87.2% being on medication.²

How Researchers Measured Hypothalamic Volume in Narcolepsy Type 1

To investigate hypothalamic changes in vivo, researchers at the IRCCS Istituto delle Scienze Neurologiche di Bologna enrolled a consecutive cohort of 75 adults with confirmed NT1 (36 women; mean age, 33.1 years) and compared them with 85 age- and sex-matched healthy controls (42 women; mean age, 32.5 years).¹ All participants underwent high-resolution 3T T1-weighted magnetization-prepared rapid gradient-echo MRI. An automated segmentation tool from FreeSurfer v7 delineated the whole hypothalamus and its 5 subregions: anterior-inferior, anterior-superior, posterior, tuberal-inferior, and tuberal-superior.

Hypothalamic Atrophy Found Across Most Subregions in NT1

After adjusting for age, sex, and total intracranial volume, patients with NT1 showed significant atrophy of the whole hypothalamus compared with healthy controls (P = .009). Volume reductions were identified in 4 of 5 subregions: anterior-inferior (P = .0008), anterior-superior (P = .003), posterior (P = .03), and tuberal-superior (P = .04). The tuberal-inferior subregion was the only area without a statistically significant difference, though a trend toward reduction was observed.

Why Atrophy Extends Beyond Orexin-Producing Neurons

The subregions showing the greatest atrophy are not those expected to harbor the largest concentrations of orexinergic cell bodies. Orexinergic neurons are located predominantly in the dorsomedial and ventromedial nuclei and lateral hypothalamus, structures mapped primarily to the tuberal-superior and tuberal-inferior subregions. The authors offer 2 mechanistic hypotheses for the pattern observed. First, the loss of orexin—whether through neuronal death or epigenetic silencing—may reduce stimulation to orexin receptors expressed across a broad range of hypothalamic neurons, causing downstream "functional" atrophy. Second, the death of orexinergic neurons may trigger degeneration of their extensive axonal projections throughout the hypothalamus, resulting in volume loss in regions that are not the primary site of neuronal loss.

The relative preservation of the tuberal-inferior subregion may reflect compensatory changes. Prior histopathological work has documented a marked increase in histaminergic neurons at the tuberomammillary nucleus in patients with NT1, a region mapped to the tuberal-inferior segment. The authors suggest that volumetric gains from histaminergic neuronal proliferation may offset atrophy from orexin neuron loss, producing a net null effect detectable by MRI.

Hypothalamic Volume Not Correlated With Disease Duration or Orexin Levels

No significant correlations emerged between hypothalamic volumes and clinical or laboratory variables, including disease duration, Epworth Sleepiness Scale scores, cataplexy frequency, or cerebrospinal fluid orexin levels. The authors interpret the absence of a duration-volume relationship as consistent with the view that hypothalamic atrophy in NT1 is established early in the disease course and does not progress substantially over time—a structural residue of an acute, early immune-mediated event rather than a marker of ongoing neurodegeneration.

Study Limitations and Implications for Future Research

The study is cross-sectional, limiting causal inference, and did not include pediatric patients, a population of particular interest given that NT1 typically emerges in childhood or early adulthood. The authors acknowledge that MRI segmentation based on gross anatomy cannot resolve the cellular-level changes visible on histology, and they call for future pathological studies to clarify whether the atrophy reflects neuroinflammation, gliosis, cellular remodeling, or some combination of these processes. They also note that quantitative hypothalamic MRI could eventually serve as a noninvasive biomarker for NT1.

“These findings may relate to a pathological process that extends throughout the hypothalamus, beyond the orexin neurons,” the authors concluded. “The sparing of tuberal-inferior region might be linked to neuroinflammatory gliosis or a compensatory increase in histaminergic neurons, a hypothesis calling for future anatomical studies. Other imaging studies are needed to contribute to understanding the underlying pathological process in NT1 and to clarify if quantitative imaging studies could become a potential biomarker of NT1 disease for the future.”

References

1. Motta L, Venturi G, Biscarini F, et al. Hypothalamic volume reduction in adult patients with narcolepsy type 1. Sleep. 2026;49(6):zsag087. doi:10.1093/sleep/zsag087
2. Bonavitacola J. Patients with narcolepsy experience significant burden of disease. AJMC. June 17, 2026. Accessed June 25, 2026. https://www.ajmc.com/view/patients-with-narcolepsy-experience-significant-burden-of-disease